Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

BACKGROUND: Memantine is licensed for moderate-to-severe Alzheimer's disease (AD). National Institute for Clinical Excellence (NICE) guidance does not recommend the use of memantine in combination with cholinesterase inhibitors (acetylcholinesterase inhibitor (AChEI)). The underpinning meta-ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Farrimond, Lucy E, Roberts, Emmert, McShane, Rupert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Group 2012
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378937/
https://www.ncbi.nlm.nih.gov/pubmed/22689908
http://dx.doi.org/10.1136/bmjopen-2012-000917

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378937/
https://www.ncbi.nlm.nih.gov/pubmed/22689908
http://dx.doi.org/10.1136/bmjopen-2012-000917

Ejemplares similares